Stock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally

Stock Track

Jul 02

SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.

The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.

Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1123977572"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123977572\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123977572?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123977572","market":"us","top_or_hot":-1,"title":"Stock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally","media":"Stock Track","content":"<p>SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.</p><p>The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.</p><p>Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-02 10:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.</p><p>The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.</p><p>Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1123977572","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123977572","pubTimestamp":1782958283,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.The surge appears driven by multiple positive developments...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"个股追踪|SBP集团盘中大涨7.26%，因战略AI投资、药物获批和板块反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}